Compare TORO & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TORO | BDSX |
|---|---|---|
| Founded | 2022 | 2005 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.9M | 143.2M |
| IPO Year | 2022 | 2020 |
| Metric | TORO | BDSX |
|---|---|---|
| Price | $5.33 | $14.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | ★ 248.4K | 67.6K |
| Earning Date | 04-15-2026 | 05-04-2026 |
| Dividend Yield | ★ 36.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $25.26 |
| Revenue Next Year | N/A | $19.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $1.81 | $0.26 |
| 52 Week High | $8.50 | $20.21 |
| Indicator | TORO | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 56.29 |
| Support Level | $5.06 | $13.46 |
| Resistance Level | $5.94 | $16.38 |
| Average True Range (ATR) | 0.49 | 1.09 |
| MACD | -0.13 | 0.11 |
| Stochastic Oscillator | 17.33 | 48.74 |
Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.